Screener
Medpace Holdings, Inc. MEDP Metabolic — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Therapeutic Area | ||||
| Metabolic | $219,067 | $147,873 | $456,625 | $295,888 |
| Oncology | 209,372 | 188,558 | 410,611 | 359,034 |
| Other | 98,279 | 118,062 | 191,597 | 213,898 |
| Central Nervous System | 82,858 | 61,129 | 163,065 | 116,030 |
| Cardiology | 59,982 | 58,584 | 116,243 | 116,863 |
| AVAI | 37,773 | 29,105 | 75,794 | 60,168 |
| Total revenue | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s metabolic — total revenue?
- Medpace Holdings, Inc. (MEDP) reported metabolic — total revenue of $209.37M in Q2 2026.
- How has Medpace Holdings, Inc.'s metabolic — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s metabolic — total revenue increased by 11.0% year-over-year, from $188.56M to $209.37M.
- What is the long-term trend for Medpace Holdings, Inc.'s metabolic — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s metabolic — total revenue has grown at a 19.8% compound annual growth rate (CAGR), from $362.85M to $747.59M.
- What does metabolic — total revenue mean?
- This metric represents the total gross income generated specifically from clinical research and development services provided to clients within the metabolic therapeutic area. It captures the financial performance of the company's specialized expertise in managing trials for metabolic diseases, including diabetes, obesity, and related endocrine disorders. This revenue stream reflects the company's ability to capture market share and deliver value within this specific high-demand segment of the pharmaceutical development lifecycle.
Ask your AI about Medpace Holdings, Inc.'s metabolic — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude